• Trinity Biotech agreed in principle to make a strategic equity investment in Latch Medical as part of a new collaboration.
• Deal positions Trinity Biotech as a minority shareholder in Latch Medical alongside the partnership.
• Investment aims to support development of biosensor-guided precision drug delivery using Trinity Biotech’s CGM+ platform with Latch Medical’s Pharma Latch technology.
• Perceptive Advisors, Trinity Biotech’s largest financial investor, will support the planned equity investment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220730PRIMZONEFULLFEED9766271) on July 22, 2026, and is solely responsible for the information contained therein.